OliPass Corp
KOSDAQ:244460
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
OliPass Corp
Depreciation & Amortization
OliPass Corp
Depreciation & Amortization Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Depreciation & Amortization | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
O
|
OliPass Corp
KOSDAQ:244460
|
Depreciation & Amortization
-₩1.4B
|
CAGR 3-Years
3%
|
CAGR 5-Years
5%
|
CAGR 10-Years
N/A
|
|
|
Celltrion Inc
KRX:068270
|
Depreciation & Amortization
-₩70.8B
|
CAGR 3-Years
-17%
|
CAGR 5-Years
-41%
|
CAGR 10-Years
-22%
|
|
|
O
|
OliX Pharmaceuticals Inc
KOSDAQ:226950
|
Depreciation & Amortization
-₩1.3B
|
CAGR 3-Years
-5%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
N/A
|
|
|
V
|
Voronoi Inc
KOSDAQ:310210
|
Depreciation & Amortization
-₩2B
|
CAGR 3-Years
15%
|
CAGR 5-Years
6%
|
CAGR 10-Years
N/A
|
|
|
Alteogen Inc
KOSDAQ:196170
|
Depreciation & Amortization
-₩3.6B
|
CAGR 3-Years
-80%
|
CAGR 5-Years
-58%
|
CAGR 10-Years
-62%
|
|
|
A
|
ABL Bio Inc
KOSDAQ:298380
|
Depreciation & Amortization
-₩3.4B
|
CAGR 3-Years
-14%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
N/A
|
|
OliPass Corp
Glance View
OliPass Corp. develops biological products. The company is headquartered in Yongin, Gyeonggi-Do. The company went IPO on 2019-09-20. The firm principally manufactures and sells nonopioid analgesic, hyperlipidemia medicine, ocular angiogenesis inhibitor, duchenne dystrophy medicine, cancer immunotherapy medicine and other products. In addition, the Company researches, develops and sells functional cosmetics through the artificial gene platform technology.
See Also
What is OliPass Corp's Depreciation & Amortization?
Depreciation & Amortization
-1.4B
KRW
Based on the financial report for Sep 30, 2025, OliPass Corp's Depreciation & Amortization amounts to -1.4B KRW.
What is OliPass Corp's Depreciation & Amortization growth rate?
Depreciation & Amortization CAGR 5Y
5%
Over the last year, the Depreciation & Amortization growth was -207%. The average annual Depreciation & Amortization growth rates for OliPass Corp have been 3% over the past three years , 5% over the past five years .
